Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate Deployment of Next-Generation Immunoassay Technology
August 5, 2025 – Spear Bio, a pioneering biotechnology company specializing in homogeneous ultrasensitive immunoassay technology, has announced a strategic distribution partnership with Bio-Techne Corporation. Bio-Techne is a globally recognized leader in providing innovative reagents, instruments, and solutions for life-science research and clinical diagnostics. This collaboration aims to significantly enhance global access to Spear Bio’s cutting-edge immunoassay technology, initially focusing on the neurology research market.
Expanding Access to Breakthrough Immunoassays for Neurodegenerative Research
The partnership will focus on the global deployment of Spear Bio’s SPEAR UltraDetect™ immunoassays, a next-generation platform offering unprecedented sensitivity for biomarker detection. The initial product lineup targets key biomarkers associated with neurodegenerative diseases, including phosphorylated tau proteins 231 (pTau 231) and 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light (Nf-L). These biomarkers are crucial for advancing the understanding, early detection, and treatment development of conditions such as Alzheimer’s disease and other neurological disorders.
Advanced Technology Backed by Harvard Innovation
Spear Bio’s SPEAR platform utilizes Successive Proximity Extension Amplification Reaction, a breakthrough technology licensed from Harvard University. This technology is designed for use with conventional qPCR instruments and provides sensitivity improvements two to three orders of magnitude beyond current immunoassay platforms. Early and accurate detection of protein biomarkers holds the potential to unlock deeper insights into disease mechanisms, facilitate early intervention strategies, and accelerate clinical trials.
Strategic Collaboration Building on Previous Investment
This partnership follows Bio-Techne’s participation in Spear Bio’s $45 million Series A funding round in 2024, signaling strong confidence in the transformative potential of the SPEAR technology. The collaboration leverages Bio-Techne’s extensive global distribution network and expertise in immunoassay development to expand the reach of Spear Bio’s technology, accelerating biomarker research and diagnostic development worldwide.
Statements from Leadership
Will Geist, President of Bio-Techne’s Protein Sciences Segment, expressed enthusiasm about the partnership, stating, “Partnering with Spear Bio marks an exciting step in our mission to advance biomarker detection in neurodegenerative disease research. By combining our global reach and immunoassay expertise with Spear Bio’s ultrasensitive technology, we are equipping researchers with innovative tools to detect and study critical biomarkers with unmatched precision and sensitivity.”
Feng Xuan, PhD, Founder and CEO of Spear Bio, highlighted the transformative potential, commenting, “Our strategic partnership with Bio-Techne represents an extraordinary opportunity for neurodegenerative disease research. By combining Bio-Techne’s global distribution network and market leadership with Spear Bio’s next-generation immunoassay technology, we are empowering researchers worldwide to investigate earlier disease mechanisms, improve patient stratification in clinical trials, and accelerate the development of new treatments for neurological disorders.”
Broader Implications and Future Applications
While the initial focus of the SPEAR UltraDetect platform targets neurodegenerative disease biomarkers, the technology’s applications also extend to inflammation, oncology, and other key life science fields. The enhanced sensitivity and precision offered by this platform open doors to advancing early diagnosis and treatment strategies across a range of challenging medical conditions, thereby ultimately improving patient outcomes.
About Spear Bio and Bio-Techne
Spear Bio is dedicated to revolutionizing biomarker detection with its proprietary SPEAR technology, offering ultrasensitive immunoassays for critical disease research areas. Bio-Techne Corporation is a global leader in life-science research and clinical diagnostics, known for its innovative reagents, instruments, and solutions that empower scientific discovery and improve health outcomes worldwide.
Source: Spear Bio
For further details, visit News-Medical.net
